Renal Pathophysiology II Iain MacLeod, Ph.D [email protected] Iain MacLeod 30 November 2009

Renal Pathophysiology II

Iain MacLeod, [email protected]

Iain MacLeod 30 November 2009

Renin-Angiotensin System

• Aldosterone is produced in the adrenal cortex in response to low sodium levels

• Stimulates sodium reabsorption by distal convoluted tubules and collecting ducts

• When aldosterone is ↓ then less sodium is absorbed – the converse is true

• Aldosterone is a steroid that acts slowly to mediate changes in gene and protein expression – most

importantly, of Na/K-ATPase pumps and leak channels in the cortical collecting ducts.

• Also prevents loss of sodium via the same mechanism is salivary and sweat glands.

So what controls the release of aldosterone and therefore sodium absorption ?


Angiotensin II Aldosterone secretion

• Angiotensin II is the end product of a protein cleavage

cascade that is initiated by renin

• Renin is secreted by juxtaglomerular cells in the kidney,

where it enters the bloodstream and splits a precursor

protein, angiotensinogen, into angiotensin I.

• A further cleavage of angiotensin I, by angiotensin-

converting enzyme (ACE), yields the final mediator,

angiotensin II.

• Angiotensin II is high during salt depletion and low when

salt intake is high, so it is the regulator of aldosterone


If angiotensin II controls aldosterone release, what

controls angiotensinogen cleavage?

• Angiotensinogen and ACE are normally found in

excess, with ACE found in high concentrations on the

surface of capillary endothelial cells – thus the limiting

factor in angiotensin II formation is renin.

• Sodium depletion leads to increased renin excretion

through three inputs to juxtaglomerular cells:

• the renal sympathetic nerves

• intrarenal baroreceptors

• the macula densa


Renal sympathetic nerves:

• activated when low sodium leads to low plasma volume and therefore low blood pressure

• innervate the juxtaglomerular cells and stimulate renin secretion





Intrarenal baroreceptors

• Juxtaglomerular cells, as a function of being found in the walls of the afferent arterioles, are

sensitive to changes in blood pressure within the kidneys

• Less stretching of the walls, due to a decrease in pressure, leads to an increase in renin





Intrarenal baroreceptors

• Juxtaglomerular cells, as a function of being found in the walls of the afferent arterioles, are

sensitive to changes in blood pressure within the kidneys

• Less stretching of the walls, due to a decrease in pressure, leads to an increase in renin

Macula densa

• Located near the loops of Henle – senses sodium conc. in tubular fluid that passes through

• Additionally, decreased sodium decreased GFR decreased tubular flow

• Both of these inputs result in the further secretion of renin

System has multiple redundancies to prevent further loss of sodium and decreasing blood pressure


Diabetic Kidney Disease (DKD)


African Americans, American Indians, and Hispanics/Latinos develop diabetes, CKD, and kidney failure at rates higher than Caucasians.

Interplay of factors leading to kidney disease of diabetes—factors including heredity, diet, and other medical conditions, such as high blood pressure.

High blood pressure and high levels of blood glucose increase the risk that a person with diabetes will progress to kidney failure.

Type 1 vs. Type 2?


• Diabetes mellitus (DM) now accounts for more cases of end-stage renal disease (ESRD) than any

other cause of chronic kidney disease (CKD).

• In the USA, four out of every 10 new cases of ESRD arise due to diabetic kidney disease (DKD)

• Roughly 30% of individuals with type 1 and 10% of those with type 2 diabetes will develop DKD

• Glycemic control along with currently available pharmacotherapies slow, but do not stop, the

progression of DKD towards ESRD - for these patients, the only available solution is renal replacement

therapy (i.e., transplantation or dialysis).

• Given the epidemic levels of obesity and type 2 DM in the populations of many Western nations, a

comprehensive understanding of the etiology of DKD is urgently needed so that novel therapies can be

developed.


• Many efforts are being aimed at identifying the earliest signs of DKD so that treatments can be

instituted before irreversible renal injury occurs.

• It is now widely recognized that proteinuria, specifically microalbuminuria, is one of the earliest

clinically identifiable markers of diabetes-induced renal damage.

• The appearance of protein in the urine (predominantly the 67-kDa albumin) indicates a compromised

glomerular filtration barrier.

• A strong correlation has been identified between the likelihood of progression to ESRD and the level

of albuminuria - now considered a continuous variable in that even quantities of albumin that are in

the upper end of what is considered the “normal” range (<30 mg/day) are associated with an increased

risk for the development of later-stage chronic kidney disease.

• Individuals with DKD presenting with a high urinary protein excretion rate advance more quickly to

ESRD than do those with low proteinuria

Diabetic Kidney Disease (DKD) - Podocytopathies

• Classical view - passage of

albumin into Bowman’s space is

overwhelmingly impeded by the

size- and charge-selective

glomerular filtration barrier

consisting of three

interdependent layers: the

endothelial cells, the glomerular

basement membrane (GBM), and

the podocytes. • Morphologically intricate podocyte and its slit diaphragm structure are of primary importance to the

maintenance of the filtration barrier, and that injury to this cell is a key event in the initiation of DKD.

• Studies of diabetic patients and animal models reveal that the onset of albuminuria is most closely

associated with podocytopathies, such as foot process effacement (reduction in surface area), podocyte

hypertrophy, detachment, apoptosis, and epithelial-to-mesenchymal transition


• Thought that proteinuria is not simply an

indicator of glomerular damage, nor just a

predictor progression, but has causative effects on

these disease processes. Excessive albumin levels

likely overwhelm the metabolic capacity of the

renal tubules, thereby promoting inflammation

leading to tubulointerstitial fibrosis and an

ensuing reduction of glomerular filtration rate

(GFR).

Glomerulosclerosis

Mediators of Podocytopathies in DKD

The Renin-Angiotensin System (RAS)

• RAS has been implicated in the progression of DKD - angiotensin-converting enzyme inhibitors (ACEi)

and angiotensin II receptor blockers (ARBs) slow disease progression

• ACEi and ARBs were thought to improve the clinical outcome in diabetic patients via their blood

pressure–lowering effects, acting, in part, to mitigate hyperfiltration-enhanced glomerular capillary

pressure (Pgc) - the podocyte is susceptible to the mechanical forces brought about by elevated Pgc.

• However, under conditions that reproduce a diabetic milieu (e.g., high glucose, mechanical stretch),

podocytes are driven to express several RAS components, including angiotensinogen, with angiotensin

I and II levels appeared to be enhanced by high glucose.

• Locally acting RAS that appears to induce apoptosis and TGF-β (important for fibrosis)

Mediators of Podocytopathies in DKD

Reactive Oxygen Species (ROS)

• Within the kidney, as in other organs and tissues (i.e., vasculature), hyperglycemia and RAS activation

promote oxidative stress, defined as damage to macromolecules caused by ROS (i.e., O2–, H2O2, NO,

and ONOO–)

• Studies have shown that exposure of cultured mouse podocytes to high glucose promoted ROS

generation and possible downregulation of other mediators – eNOS-deficient db/db mice display

severe glomerular lesions and albuminuria

• ROS generation in the podocyte may have other deleterious roles in addition to its proapoptotic

actions. ROS could induce actin filament polymerization, leading to cytoskeletal dysfunction and

resulting in structural changes to foot processes and slit diaphragms.

Treatment for DKD ?

C-Peptide

• Produced as a result of cleavage of pro-insulin into function insulin

• Is not just a by-product – is capable of binding to cellular receptors and altering gene expression

Bardoxolone methyl

• Antioxidant inflammation modulator

• In 21-day phase 1 trial in 60 oncology patients showed a favorable response in 49 patients (82%).

Serum creatinine levels decreased a mean of 19.3%, and estimated glomerular filtration rate (eGFR)

increased a mean of 20.9%. The effect appeared to be greater in patients with established chronic

kidney disease (CKD; 13 of 60 patients); in these patients, eGFR increased a mean of 27.6%.

Olmesartan medoxomil – angiotensin II receptor blocker

Documents

Renal Pathophysiology II Iain MacLeod, Ph.D [email protected] Iain MacLeod 30 November 2009